Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin DehayInstitute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, 33076 Bordeaux, FranceMathieu BourdenxInstitute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, 33076 Bordeaux, FrancePhilippe GorryResearch Unit of Theoretical & Applied Economics, University of Bordeaux, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5113, 33608 Pessac, FranceSerge PrzedborskiDepartments of Neurology, Pathology and Cell Biology, and the Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USAMiquel VilaCatalan Institution for Research and Advanced Studies, 08010 Barcelona, SpainStéphane HunotCNRS, UMR 7225, ICM, Paris, FranceAndrew SingletonMolecular Genetics Section and Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD20892, USAC. Warren OlanowDepartments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10032, USAKalpana MerchantErwan BézardInstitute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, 33076 Bordeaux, FranceGregory A. PetskoDepartment of Neurology and Feil Family Brain and Mind research Institute, Weill Cornell Medical College, New York NY 10021, USAWassilios G. MeissnerInstitute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, 33076 Bordeaux, France
2015en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0